GIA
NBIX icon

GHP Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

GHP Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54K Hold
21
– – ﹤0.01% 940
2026
Q1 		$2.77K Buy
21
+1
+5% +$133 ﹤0.01% 971
2025
Q4 		$2.84K Buy
+20
New +$2.9K ﹤0.01% 875
2024
Q3 		– Sell
-77
Closed -$10.6K – 1047
2024
Q2 		$10.6K Buy
+77
New +$10.6K ﹤0.01% 681

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GHP Investment Advisors's NBIX Position: Q2 2026 in Review

GHP Investment Advisors held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 21 shares worth $3.54K. The position accounts for ﹤0.01% of the portfolio, ranked #940.

GHP Investment Advisors first reported a position in NBIX in Q2 2024 and has held it in 4 quarters since. The position peaked at $10.6K in Q2 2024. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • GHP Investment Advisors held 21 shares of Neurocrine Biosciences worth $3.54K as of Q2 2026.
  • GHP Investment Advisors left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #940 holding.
  • GHP Investment Advisors first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 4 quarters since.
  • GHP Investment Advisors's Neurocrine Biosciences position peaked at $10.6K in Q2 2024.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.